Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
Syndax's Revuforj (revumenib), the company's first-in-class menin inhibitor, was selected by TIME as one of the Best Inventions of 2026 in the Medical and Healthcare category. Revuforj is the only FDA-approved menin inhibitor, indicated for relapsed or refractory acute leukemia with a KMT2A translocation (approved November 2024) or a susceptible NPM1 mutation (expanded October 2025).
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.